Drug of the month. Sildenafil (Viagra)
Abstract
Sildenafil (Viagra) from Pfizer (UK-92,480) is a competitive and selective inhibitor of cyclic GMP specific type 5 phosphodiesterase. Male erectile dysfunction is defined as "the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance". Sildenafil (Viagra) is effective in a significant proportion of patients with erectile dysfunction. Patients should be instructed to take a dose from 25 to 100 mgrs approximately 30 to 60 minutes before sexual activity, but no more than once daily. Sexual stimulation is necessary to produce erectile reaction. The safety and tolerance of sildenafil have been demonstrated. However, prior to initiating treatment with sildenafil, physicians should consider the cardiovascular status of their patients, particularly for patients with unstable coronary heart disease or concomitant treatment with nitrates.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.